FluWatch report: November 30 to December 6, 2014 (Week 49)
Overall summary
- In week 49, laboratory detections of influenza increased sharply for the third consecutive week. The majority of laboratory detections continued to be reported in BC, AB, ON and QC; but with increasing activity in SK and NS.
- A(H3N2) continues to be the most common type of influenza affecting Canadians. In both laboratory detections and hospitalizations, the majority of cases have been among seniors ≥65 years of age.
- Similar to the previous week, there were a large number of newly-reported laboratory-confirmed outbreaks of influenza: 37 influenza A outbreaks in 6 provinces, of which 32 were in long-term care facilities (LTCF). Among the outbreaks with known subtype all were due to A(H3N2).
- The rate of antiviral prescriptions among seniors increased significantly in week 49.
Are you a primary health care practitioner (General Practitioner, Nurse Practitioner or Registered Nurse) interested in becoming a FluWatch sentinel for the 2014-15 influenza season? Contact us at FluWatch@phac-aspc.gc.ca
On this page
- Influenza/ILI Activity (geographic spread)
- Influenza and Other Respiratory Virus Detections
- Antiviral Resistance
- Influenza Strain Characterizations
- Influenza-like Illness (ILI) Consultation Rate
- Influenza Outbreak Surveillance
- Pharmacy surveillance
- Sentinel Hospital Influenza Surveillance
- Provincial/Territorial Influenza Hospitalizations and Deaths
- Emerging Respiratory Pathogens
- International Influenza Reports

Download the alternative format
(PDF format, 307 KB, 10 pages)
Related Topics
Influenza/ILI Activity (geographic spread)
In week 49, two regions reported widespread activity (QC (1), BC(1)), six regions reported localized activity (BC(1), AB(3), SK(1), ON(5), QC(2), and NS(1)), and nine regions (in BC(2), AB(2), SK(2), MB(1), QC(3), NB(1), PE(1), YK(1), and NT(1)) reported sporadic activity (Figure 1).
Figure 1. Map of overall influenza/ILI activity level by province and territory, Canada, Week 49
Note: Influenza/ILI activity levels, as represented on this map, are assigned and reported by Provincial and Territorial Ministries of Health, based on laboratory confirmations, sentinel ILI rates and reported outbreaks. Please refer to detailed definitions at the end of the report. Maps from previous weeks, including any retrospective updates, are available on the Flu Activity website.
Figure 1 Map of overall influenza/ILI activity level by province and territory, Canada, Week 30 - Text Description
Influenza and Other Respiratory Virus Detections
In week 49, the number of positive influenza tests increased sharply for the third week in a row, to 1,011 influenza detections (19.5% of tests), predominantly due to influenza A (Figure 2). To date, 95% of influenza detections have been influenza A, and 99.5% of those subtyped have been A(H3) (Table 1). The timing of the season and predominant A(H3N2) subtype is similar to the pattern observed during the 2012-13 influenza season when percent positive for influenza peaked in week 52 (35%). To date, among the cases of influenza with reported age, the largest proportion was in adults ≥65 years of age (52.2%) (Table 2).
Figure 2. Number of positive influenza tests and percentage of tests positive, by type, subtype and report week, Canada, 2014-15

Figure 2 - Text Description
In week 49, the number of positive influenza tests increased sharply for the third week in a row, to 1,011 influenza detections (19.5% of tests), predominantly due to influenza A.
In week 49, detections of RSV were similar to the previous week, keeping with its usual pattern of seasonal circulation. Detections of parainfluenza and adenovirus also continue to follow their seasonal patterns of broad winter circulation. Detections of rhinovirus peaked in week 39 and continue to follow a downward trend (figure 3).
For more details, see the weekly Respiratory Virus Detections in Canada Report.
Figure 3. Number of positive laboratory tests for other respiratory viruses by report week, Canada, 2014-15

RSV: Respiratory syncytial virus; hMPV: Human metapneumovirus
Figure 3 Number of positive laboratory tests for other respiratory viruses by report week, Canada, 2014-15 - Text Description
Reporting provincesFootnote 1 | Weekly (November 30 to December 6, 2014) | Cumulative (August 24 to December 6, 2014) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Influenza A | B | Influenza A | B | |||||||
A Total | A(H1)pdm09 | A(H3) | A Footnote (Uns) | B Total | A Total | A(H1)pdm09 | A(H3) | A(UnS) | B Total | |
BC | 55 | 0 | 41 | 14 | 2 | 180 | 2 | 163 | 15 | 11 |
AB | 323 | 0 | 189 | 134 | 11 | 916 | 0 | 767 | 149 | 42 |
SK | 34 | 0 | 12 | 22 | 1 | 60 | 0 | 23 | 37 | 1 |
MB | 2 | 0 | 2 | 0 | 0 | 14 | 0 | 14 | 0 | 1 |
ON | 132 | 0 | 105 | 27 | 2 | 340 | 4 | 259 | 77 | 18 |
QC | 413 | 0 | 0 | 413 | 18 | 824 | 0 | 0 | 824 | 48 |
NB | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 2 | 0 |
NS | 6 | 0 | 6 | 0 | 0 | 7 | 0 | 7 | 0 | 2 |
PE | 1 | 0 | 1 | 0 | 0 | 5 | 0 | 4 | 1 | 1 |
NL | 3 | 0 | 0 | 3 | 0 | 5 | 0 | 1 | 4 | 0 |
Canada | 969 | 0 | 356 | 613 | 34 | 2354 | 6 | 1239 | 1109 | 124 |
Percentage Footnote 2 | 96.6% | 0.0% | 36.7% | 63.3% | 3.4% | 95.0% | 0.3% | 52.6% | 47.1% | 5.0% |
Age groups (years) | Weekly (November 30 to December 6, 2014) |
Cumulative (August 24 to December 6, 2014) |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Influenza A | B | Influenza A | B | Influenza A and B | ||||||||
A Total | A(H1) pdm09 | A(H3) | A Footnote (Uns) | Total | A Total | A(H1) pdm09 | A(H3) | A (UnS) | Total | # | % | |
<5 | 60 | 0 | 26 | 34 | 6 | 210 | 4 | 138 | 68 | 19 | 229 | 9.8% |
5-19 | 81 | 0 | 27 | 54 | 6 | 237 | 0 | 153 | 84 | 25 | 262 | 11.2% |
20-44 | 107 | 0 | 43 | 64 | 5 | 321 | 0 | 186 | 135 | 16 | 337 | 14.4% |
45-64 | 93 | 0 | 26 | 67 | 4 | 266 | 0 | 112 | 154 | 25 | 291 | 12.4% |
65+ | 426 | 0 | 85 | 341 | 7 | 1194 | 2 | 456 | 736 | 31 | 1225 | 52.2% |
Unknown | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0.1% |
Total | 767 | 0 | 207 | 560 | 28 | 2229 | 6 | 1045 | 1178 | 116 | 2345 | 100.0% |
PercentageFootnote 2 | 96.5% | 0.0% | 27.0% | 73.0% | 3.5% | 95.1% | 0.3% | 46.9% | 52.8% | 4.9% | ||
Influenza Strain Characterizations
During the 2014-2015 influenza season, the National Microbiology Laboratory (NML) has characterized 25 influenza viruses [11 A(H3N2) and 14 influenza B]. When tested by hemagglutination inhibition (HI) assay, two influenza A viruses were antigenically similar to A/Texas/50/2012, and 11 influenza B viruses were antigenically similar to the B/Massachusetts/2/2012 (Yamagata lineage) recommended by the WHO for the 2014-15 seasonal influenza vaccine. Nine influenza A(H3N2) viruses and three influenza B viruses showed reduced titers to antisera produced against strains recommended for the seasonal influenza vaccine (Figure 4). Additionally, 38 A(H3N2) viruses were unable to be tested by HI assay; however, sequence analysis showed that they belonged to a genetic group that typically shows reduced titers to A/Texas/50/2012.
Figure 4. Influenza strain characterizations, Canada, 2014-2015, N = 25

The NML receives a proportion of the number of influenza positive specimens from provincial laboratories for strain characterization and antiviral resistance testing. Characterization data reflect the results of haemagglutination inhibition (HAI) testing compared to the reference influenza strains recommended by WHO.
The recommended components for the 2014-2015 northern hemisphere trivalent influenza vaccine include: an A/California/7/2009(H1N1)pdm09-like virus, an A/Texas/50/2012 (H3N2)-like virus, and a B/Massachusetts/2/2012-like virus (Yamagata lineage). For quadrivalent vaccines, the addition of a B/Brisbane/60/2008-like virus is recommended.
Figure 4 - Text Description
Strain | Number of specimens | Percentage |
---|---|---|
A/Texas/50/2012-like | 2 | 8% |
reduced titres to A/Texas/50/2012 | 9 | 36% |
A/California/07/2009-like | 0 | 0% |
reduced titres to A/California/07/2009 | 0 | 0% |
B/Massachusetts/2/2012-like | 11 | 44% |
reduced titres to B/Massachusetts/2/2012 | 3 | 12% |
B/Brisbane/60/2008-like | 0 | 0% |
Antiviral Resistance
During the 2014-2015 influenza season, NML has tested 74 influenza viruses for resistance to oseltamivir and zanamivir and all were sensitive to both agents. The 70 influenza A(H3N2) viruses tested for amantadine resistance were all resistant (Table 3).
Virus type and subtype | Oseltamivir | Zanamivir | Amantadine | |||
---|---|---|---|---|---|---|
# tested | # resistant (%) | # tested | # resistant (%) | # tested | # resistant (%) | |
A (H3N2) | 60 | 0 | 60 | 0 | 70 | 70 (100%) |
A (H1N1) | 0 | 0 | 0 | 0 | 0 | 0 |
B | 14 | 0 | 14 | 0 | NATable 3 - Footnote * | NA Table 3 - Footnote * |
TOTAL | 74 | 0 | 74 | 0 | 70 | 70 |
Influenza-like Illness (ILI) Consultation Rate
The national influenza-like-illness (ILI) consultation rate increased in week 49 to 44.3 consultations per 1,000, which is above expected levels for week 49 (Figure 5). This week, the rates were highest among the 20 to 64 years of age group. In previous weeks, the ILI consultation rates of this group have been among the lowest.
Figure 5. Influenza-like-illness (ILI) consultation rates by report week, compared to the 1996-97 through to 2012-13 seasons (with pandemic data suppressed), Canada, 2014-2015

No data available for mean rate for weeks 19 to 39 for the 1996-1997 through 2002-2003 seasons. Delays in the reporting of data may cause data to change retrospectively. The calculation of the average ILI consultation rate over 17 seasons was aligned with influenza activity in each season. In BC, AB, and SK, data is compiled by a provincial sentinel surveillance program for reporting to FluWatch. Not all sentinel physicians report every week.
Figure 5 - Text Description
The national influenza-like-illness (ILI) consultation rate increased in week 49 to 44.3 consultations per 1,000, which is above expected levels for week 49.
Influenza Outbreak Surveillance
In week 49, 37 new outbreaks of influenza A were reported: 32 in long-term care facilities (LTCF), two in hospitals and three in institutional or community settings (Figure 6). An additional three outbreaks of ILI were reported in schools. Among the outbreaks in which the influenza subtype was known, four LTCF outbreaks and one hospital outbreak were associated with A(H3N2). To date this season, 84 outbreaks in LTCF have been reported.
Figure 6: Overall number of new laboratory-confirmed influenza outbreaks by report week, Canada, 2014-2015

1 All provinces and territories except NU report outbreaks in long-term care facilities. All provinces and territories with the exception of NU and QC report outbreaks in hospitals. Outbreaks of influenza or influenza-like-illness in other facilities are reported to FluWatch but reporting varies between jurisdictions. Outbreak definitions are included at the end of the report.
Figure 6 - Text Description
Report week | Hospitals | Long Term Care Facilities | Other |
---|---|---|---|
35 | 0 | 0 | 0 |
36 | 0 | 0 | 0 |
37 | 0 | 0 | 0 |
38 | 0 | 1 | 0 |
39 | 0 | 5 | 1 |
40 | 0 | 0 | 0 |
41 | 0 | 2 | 0 |
42 | 0 | 3 | 0 |
43 | 0 | 2 | 0 |
44 | 0 | 1 | 0 |
45 | 0 | 2 | 0 |
46 | 0 | 3 | 0 |
47 | 0 | 16 | 1 |
48 | 3 | 17 | 1 |
49 | 2 | 32 | 3 |
Pharmacy surveillance
During week 49, the proportion of prescriptions for antivirals increased to 92.8 antiviral prescriptions per 100,000 total prescriptions, which is slightly higher than previous seasons (Figure 7). The rates in all age groups increased from the previous week; however, the rate increased six-fold among seniors.
Figure 7. Proportion of prescription sales for influenza antivirals by age-group and week, Canada, 2014-15

Note: Pharmacy sales data are provided to the Public Health Agency of Canada by Rx Canada Inc. and sourced from major retail drug chains representing over 2,500 stores nationwide (excluding Nunavut) in 85% of Health Regions. Data provided include the number of new antiviral prescriptions (for Tamiflu and Relenza) and the total number of new prescriptions dispensed by Province/Territory and age group. Age-groups: Infant: 0-2y, Child: 2-18y; Adult: 19-64y, Senior: ≥65y
Figure 7 - Text Description
Proportion of antiviral prescriptions per 100,000 total prescriptions in week 49 for the current season compared to previous seasons:
2014-15: 92.8; 2013-14: 25.8; 2012-13: 73.8; 2011-12: 22.6
Proportion of antiviral prescriptions by age-group in week 48 for the 2014-15 season:
Infant: 46.6; child: 112.7; adult: 62.5; senior: 139.5
Sentinel Hospital Influenza Surveillance
Paediatric Influenza Hospitalizations and Deaths (IMPACT)
In week 48, 13 laboratory-confirmed influenza-associated paediatric (≤16 years of age) hospitalizations were reported by the Immunization Monitoring Program Active (IMPACT) network: 12 cases of influenza A and one case of influenza B (Figure 8a). To date this season, 51 hospitalizations have been reported by the IMPACT network, 46 (90%) of which were cases of influenza A. Among cases for which the influenza A subtype was reported, 35/37 were A(H3N2). The majority of cases (67%) were in children <5 years of age (Table 4). To date, six cases were admitted to the ICU (Figure 9a).
Note: The number of hospitalizations reported through IMPACT represents a subset of all influenza-associated paediatric hospitalizations in Canada. Delays in the reporting of data may cause data to change retrospectively.
Adult Influenza Hospitalizations and Deaths (PCIRN)
In week 49, 28 laboratory-confirmed influenza-associated adult (≥16 years of age) hospitalizations were reported by the PHAC/CIHR Influenza Research Network (PCIRN) Serious Outcomes Surveillance (SOS) network. All 28 cases were influenza A (Figure 8b). To date this season, 71 cases have been reported; 70 (99%) with influenza A. The majority of cases (86%) were among adults ≥65 years of age (Table 5). Five ICU admissions have been reported and the majority of cases (80%) were adults ≥65 years of age with underlying conditions or comorbidities. One death has been reported (Figure 9b).
Note: The number of hospitalizations reported through CIRN represents a subset of all influenza-associated adult hospitalizations in Canada. Delays in the reporting of data may cause data to change retrospectively.
Age groups | Cumulative (Aug. 24, 2014 to December 6, 2014) | |||||
---|---|---|---|---|---|---|
Influenza A | B | Influenza A and B | ||||
A Total | A(H1) pdm09 | A(H3) | AFootnote (Uns) | Total | # (%) | |
0-5m | 9 | 0 | 8 | 1 | 2 | 11 (11.6%) |
6-23m | 16 | 1 | 8 | 7 | 0 | 16 (16.8%) |
2-4y | 26 | 1 | 19 | 6 | 5 | 31 (32.6%) |
5-9y | 22 | 0 | 15 | 7 | 4 | 26 (27.4%) |
10-16y | 9 | 0 | 5 | 4 | 2 | 11 (11.6%) |
Total | 82 | 2 | 55 | 25 | 13 | 95 |
% Footnote 1 | 86.3% | 2.4% | 67.1% | 30.5% | 13.7% | 100.0% |
Age groups | Cumulative (November 15, 2014 to December 6, 2015) | |||||
---|---|---|---|---|---|---|
Influenza A | B | Influenza A and B | ||||
A Total | A(H1) pdm09 | A(H3) | AFootnote (Uns) | Total | # (%) | |
16-20 | 2 | 0 | 0 | 2 | 0 | 2 (3%) |
20-44 | 3 | 0 | 1 | 2 | 1 | 4 (6%) |
45-64 | 4 | 0 | 1 | 3 | 0 | 4 (6%) |
65+ | 61 | 0 | 9 | 52 | 0 | 61 (86%) |
Total | 70 | 0 | 11 | 59 | 1 | 71 |
% Footnote 1 | 99% | 0% | 16% | 84% | 1% | 100% |
Figure 8 - Number of cases of influenza reported by sentinel hospital networks, by week, Canada, 2014-15
A) Paediatric hospitalizations (≤16 years of age, IMPACT)

Figure 8A - Text Description
Report week | Influenza A | Influenza B |
---|---|---|
35 | 0 | 0 |
36 | 0 | 0 |
37 | 2 | 0 |
38 | 1 | 0 |
39 | 1 | 0 |
40 | 1 | 0 |
41 | 2 | 0 |
42 | 1 | 0 |
43 | 3 | 2 |
44 | 4 | 0 |
45 | 4 | 0 |
46 | 11 | 3 |
47 | 8 | 1 |
48 | 19 | 5 |
49 | 26 | 2 |
B) Adult hospitalizations (≥16 year of age, PCIRN)

Figure 8B - Text Description
Semaine de déclaration | Influenza A | Influenza B | Influenza de type inconnu |
---|---|---|---|
35 | n/a | n/a | n/a |
36 | n/a | n/a | n/a |
37 | n/a | n/a | n/a |
38 | n/a | n/a | n/a |
39 | n/a | n/a | n/a |
40 | n/a | n/a | n/a |
41 | n/a | n/a | n/a |
42 | n/a | n/a | n/a |
43 | n/a | n/a | n/a |
44 | n/a | n/a | n/a |
45 | n/a | n/a | n/a |
46 | 3 | 0 | 0 |
47 | 8 | 0 | 0 |
48 | 31 | 1 | 0 |
49 | 28 | 0 | 0 |
Figure 9 - Percentage of hospitalizations, ICU admissions and deaths with influenza reported by age-group, Canada, 2014-15
A) Paediatric hospitalizations (≤16 years of age, IMPACT)

Figure 9A - Text Description
Age-group (years) | Hospitalizations (n=95) | ICU admissions (n=9) |
---|---|---|
0-5m | 11.6% | 0.0% |
6-23m | 16.8% | 11.1% |
2-4y | 32.6% | 33.3% |
5-9y | 27.4% | 22.2% |
10-16y | 11.6% | 33.3% |
Adult hospitalizations (≥16 year of age, PCIRN-SOS)

Figure 9B - Text Description
Age-group (years) | Hospitalizations (n=68) | ICU admissions(n=5) | Deaths (n=1) |
---|---|---|---|
16-20 | 2.9% | 0.0% | 0.0% |
20-44 | 5.9% | 0.0% | 0.0% |
45-64 | 5.9% | 0.0% | 0.0% |
65+ | 85.3% | 80.0% | 100% |
Provincial/Territorial Influenza Hospitalizations and Deaths
Age groups | Cumulative (24 August, 2014 to 6 December, 2014) | |||||
---|---|---|---|---|---|---|
Influenza A | B | Influenza A and B | ||||
A Total | A(H1) pdm09 | A(H3) | AFootnote (Uns) | Total | # (%) | |
0-4 years | 33 | 1 | 28 | 4 | 0 | 33 (11%) |
5-19 years | 25 | 0 | 21 | 4 | 1 | 26 (8%) |
20-44 years | 24 | 1 | 19 | 4 | 3 | 27 (9%) |
45-64 years | 33 | 0 | 25 | 8 | 2 | 35 (11%) |
65+ years | 182 | 0 | 148 | 34 | 5 | 187 (60%) |
Unknown | 4 | 0 | 4 | 0 | 0 | 4 (1%) |
Total | 301 | 2 | 245 | 54 | 11 | 312 |
Percentage Footnote 1 | 96.5% | 0.7% | 81.4% | 17.9% | 3.5% | 100.0% |
See additional data on Reported Influenza Hospitalizations and Deaths in Canada: 2009-10 to 2014-15 on the Public Health Agency of Canada website.
Emerging Respiratory Pathogens
Human Avian Influenza
Influenza A(H7N9): Since the last FluWatch report, no new laboratory-confirmed cases of human infection with avian influenza A(H7N9) virus have been reported by the World Health Organization. Globally to December 4, 2014, the WHO has been informed of a total of 458 laboratory-confirmed human cases with avian influenza A(H7N9) virus, including 177 deaths.
Documents related to the public health risk of influenza A(H7N9), as well as guidance for health professionals and advice for the public is updated regularly on the following websites:
PHAC - Avian influenza A(H7N9)
WHO - Avian Influenza A(H7N9)
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Since the last FluWatch report, no new laboratory-confirmed cases of MERS-CoV have been reported by the World Health Organization. Globally, from September 2012 to December 11, 2014, the WHO has been informed of a total of 927 laboratory-confirmed cases of infection with MERS-CoV, including 338 deaths. All cases have either occurred in the Middle East or have had direct links to a primary case infected in the Middle East. The public health risk posed by MERS-CoV in Canada remains low (see the PHAC Assessment of Public Health Risk).
Documents related to the public health risk of MERS-CoV, as well as guidance for health professionals and advice for the public is updated regularly on the following websites:
Avian Influenza A(H5)
The Canadian Food Inspection Agency (CFIA) is continuing its investigation into an outbreak of highly pathogenic avian influenza H5N2 virus in British Columbia's Fraser Valley. To date, there have been eight infected premises, with a ninth under investigation. No human cases have been reported. Avian influenza viruses do not pose risks to food safety when poultry and poultry products are properly handled and cooked. Avian influenza rarely affects humans that do not have consistent contact with infected birds. Further information on the outbreak is provided on the following CFIA website:
Enterovirus D68 (EV-D68)
Information related to enterovirus D68, as well as guidance for health professionals and advice for the public is updated regularly:
International Influenza Reports
- World Health Organization influenza update
- World Health Organization FluNet
- WHO Influenza at the human-animal interface
- Centers for Disease Control and Prevention seasonal influenza report
- European Centre for Disease Prevention and Control - epidemiological data
- South Africa Influenza surveillance report
- New Zealand Public Health Surveillance
- Australia Influenza Report
- Pan-American Health Organization Influenza Situation Report
FluWatch definitions for the 2014-2015 season
Abbreviations: Newfoundland/Labrador (NL), Prince Edward Island (PE), New Brunswick (NB), Nova Scotia (NS), Quebec (QC), Ontario (ON), Manitoba (MB), Saskatchewan (SK), Alberta (AB), British Columbia (BC), Yukon (YT), Northwest Territories (NT), Nunavut (NU).
Influenza-like-illness (ILI): Acute onset of respiratory illness with fever and cough and with one or more of the following - sore throat, arthralgia, myalgia, or prostration which is likely due to influenza. In children under 5, gastrointestinal symptoms may also be present. In patients under 5 or 65 and older, fever may not be prominent.
ILI/Influenza outbreaks
- Schools:
-
Greater than 10% absenteeism (or absenteeism that is higher (e.g. >5-10%) than expected level as determined by school or public health authority) which is likely due to ILI.
Note: it is recommended that ILI school outbreaks be laboratory confirmed at the beginning of influenza season as it may be the first indication of community transmission in an area. - Hospitals and residential institutions:
- two or more cases of ILI within a seven-day period, including at least one laboratory confirmed case. Institutional outbreaks should be reported within 24 hours of identification. Residential institutions include but not limited to long-term care facilities ( LTCF) and prisons.
- Workplace:
- Greater than 10% absenteeism on any day which is most likely due to ILI.
- Other settings:
- two or more cases of ILI within a seven-day period, including at least one laboratory confirmed case; i.e. closed communities.
Note that reporting of outbreaks of influenza/ILI from different types of facilities differs between jurisdictions.
Influenza/ILI activity level
1 = No activity: no laboratory-confirmed influenza detections in the reporting week, however, sporadically occurring ILI may be reported
2 = Sporadic: sporadically occurring ILI and lab confirmed influenza detection(s) with no outbreaks detected within the influenza surveillance region Footnote †
3 = Localized:
- evidence of increased ILIFootnote * and
- lab confirmed influenza detection(s) together with
- outbreaks in schools, hospitals, residential institutions and/or other types of facilities occurring in less than 50% of the influenza surveillance regionFootnote †
4 = Widespread:
- evidence of increased ILIFootnote * and
- lab confirmed influenza detection(s) together with
- outbreaks in schools, hospitals, residential institutions and/or other types of facilities occurring in greater than or equal to 50% of the influenza surveillance regionFootnote †
Note: ILI data may be reported through sentinel physicians, emergency room visits or health line telephone calls.
We would like to thank all the Fluwatch surveillance partners who are participating in this year's influenza surveillance program.
Page details
- Date modified: